Wei Wei: there is still room for improvement in medical biology of caring for the aged

Medical reform has been the topic of people's livelihood in recent years What kind of influence will the further deepening of medical reform bring to the pharmaceutical industry, and what kind of investment opportunities will it give birth to? On February 27, Wei Wei, an analyst of Shanghai Securities Research pharmaceutical industry, said in an interview with Caiyuan community on the Internet of securities times that the hot spots of the two sessions this year are mainly focused on promoting the development of health service industry and encouraging social capital to enter the medical field Benefiting from the policy, the fund will still favor the pharmaceutical sector, and the overvalued value and high premium rate are likely to be maintained for a certain period of time The development goal of China's health service industry is to achieve a total industrial scale of more than 8 trillion by 2020 In terms of supporting policies, it is clear to relax market access, strengthen planning layout and land security, optimize investment and financing guidance, and improve financial and tax price policies The plan for merging rural and urban residents' social endowment insurance has been determined at the executive meeting of the State Council, which is conducive to unifying the level of residents' Endowment Insurance and promoting the development of endowment service industry Wei Wei pointed out that the development of the elderly care industry is mainly conducive to the following industries: first, the field of medical devices It is expected that with the support of policies, the large-scale elderly care park will rise rapidly, and there will be a huge demand for medical monitoring equipment such as handheld monitors and integrated monitors supporting the elderly care industry, as well as domestic medical equipment such as wheelchairs, sphygmomanometers and blood glucose meters Second, hospitals invested by social capital Due to the scarcity of medical resources in China, benefiting from the establishment of a unified national basic endowment insurance system for urban and rural residents and the opinions on promoting the development of health service industry issued in September last year, social capital hospitals will usher in an opportunity for development Further deepening the reform of medical system may start from many aspects, one of which is to encourage social capital to enter the medical field For example, the number of medical services and beds provided by social capital should reach 20% of the total number of medical institutions, the number of beds in medical and health institutions per 1000 permanent residents should reach 4, and in principle, the scale of public hospitals will not be expanded In the segmented industries, medical devices and medical services will benefit from this first; secondly, some manufacturers involving the treatment drugs for aging diseases such as cardiovascular and cerebrovascular diseases will also benefit from this This year, the health and Family Planning Commission will carry out a pilot project of combining traditional Chinese medicine with elderly care services Chinese medicine is an important part of medical and health work in China Will Chinese medicine enterprises have a better development prospect in the future? Wei Wei emphasized that traditional Chinese medicine has a long history of development in China, and has good effects in the field of chronic diseases and health care, and the elderly population is also relatively recognized As cardiovascular and cerebrovascular diseases are high incidence diseases of the elderly, traditional Chinese medicine also has treatment advantages in this field, and the enterprises of cardiovascular and cerebrovascular traditional Chinese medicine will benefit first In other words, the development of traditional Chinese medicine enterprises is facing a huge opportunity - the great health industry is facing a good opportunity for development Chinese people have a long history of using traditional Chinese medicine for health care, and have a huge demand for medicine and food homologous products such as donkey hide gelatin and ginseng, which will also become a new business highlight for some traditional Chinese medicine enterprises Wei Wei believes that the absolute valuation and the valuation premium rate of the pharmaceutical and biological sectors are at a historical high As of February 25, the absolute valuation has reached 39 times, with a valuation premium rate of 377% In 2013, due to the weak performance of the secondary market as a whole and the obvious policy support of the pharmaceutical and biological industry, the excellent performance throughout the year led to the high index premium rate At the beginning of this year, the policy continued to be positive and the valuation premium rate continued to rise However, there is always a risk of falling valuation Wei Yun stressed that under the certainty of performance growth, risk aversion and overall tight market funds in the pharmaceutical sector, funds will still favor the pharmaceutical sector, and the overvalued value and high premium rate may be maintained for a certain period of time.